Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ELUT 
Elutia Inc. (ELUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
- ALL
- 1Y
- 1M
Upturn Advisory Summary
12/01/2025: ELUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.49% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.02M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 2 | Beta 0.6 | 52 Weeks Range 0.58 - 5.12 | Updated Date 12/2/2025 |
52 Weeks Range 0.58 - 5.12 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.15 | Actual -0.09 |
Profitability
Profit Margin -121.73% | Operating Margin (TTM) -131.06% |
Management Effectiveness
Return on Assets (TTM) -36.48% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 50551124 | Price to Sales(TTM) 1.29 |
Enterprise Value 50551124 | Price to Sales(TTM) 1.29 | ||
Enterprise Value to Revenue 2.32 | Enterprise Value to EBITDA -3.32 | Shares Outstanding 40349939 | Shares Floating 17990009 |
Shares Outstanding 40349939 | Shares Floating 17990009 | ||
Percent Insiders 2.46 | Percent Institutions 68.3 |
Upturn AI SWOT
Elutia Inc.
Company Overview
History and Background
Elutia Inc., formerly known as SeaSpine Holdings Corporation, is a medical technology company focused on surgical solutions for the treatment of spinal disorders. Founded in 2015, it evolved from Integra LifeSciences' spine division. Elutia made a strategic transition to regenerative technologies and tissue processing through acquisition and internal development.
Core Business Areas
- Orthobiologics: Processing and marketing of allograft and xenograft bone tissue for spine and orthopedic procedures.
- Surgical Implants: Development and distribution of spinal implant systems and surgical instruments.
- Regenerative Technologies: Creation and marketing of products that support tissue regeneration and healing in spinal and orthopedic applications.
Leadership and Structure
Daniel H. Williamson serves as Chief Executive Officer. The organizational structure includes departments for R&D, Operations, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Competitors: Medtronic (Grafton), NuVasive (Attrax), Zimmer Biomet (Grafton)
- OsteoStrandu00ae Plus: A demineralized bone matrix (DBM) fiber-based bone graft product. Market share data is not readily available. Primary competitors include Medtronic's Grafton DBM and NuVasive's Attrax Putty. Revenue information for individual product lines is not publicly disclosed.
- Competitors: Medtronic (StealthStation), Stryker (Mako)
- SurgiMapu00ae: Advanced surgical planning system. Market share data is not readily available. Main competitors are Medtronic StealthStation and Stryker Mako Robot. Revenue information for individual product lines is not publicly disclosed.
Market Dynamics
Industry Overview
The orthobiologics and spinal implant market is characterized by technological advancements, increasing demand for minimally invasive procedures, and an aging population. There's a growing focus on regenerative medicine.
Positioning
Elutia Inc. aims to be a leading provider of regenerative technologies and surgical solutions. Their focus is on innovation and differentiated products, particularly in orthobiologics.
Total Addressable Market (TAM)
The global spine surgery market is expected to reach billions of USD. Elutia aims for a significant share of the orthobiologics and spinal implants segments, positioning itself to address a substantial portion of the TAM.
Upturn SWOT Analysis
Strengths
- Focus on regenerative technologies
- Proprietary allograft processing
- Innovative product pipeline
- Established distribution network
Weaknesses
- Smaller market capitalization compared to major competitors
- Limited brand recognition
- Dependence on key products
- Past operational losses
Opportunities
- Expanding product portfolio
- Strategic acquisitions
- Partnerships with hospitals and research institutions
- Growing demand for minimally invasive procedures
Threats
- Intense competition
- Regulatory hurdles
- Pricing pressures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- NuVasive (NUVA)
- Stryker (SYK)
Competitive Landscape
Elutia is significantly smaller than its main competitors and lacks some capital. The company needs to be more innovative to compete and is behind on Market Share.
Growth Trajectory and Initiatives
Historical Growth: Growth history data not readily available.
Future Projections: Future growth data not readily available.
Recent Initiatives: Focus on expanding regenerative product offerings and optimizing the supply chain.
Summary
Elutia Inc. is a medical technology company focusing on regenerative solutions in spine and orthopedics, which positions it well in a growing market. However, its smaller size compared to giants like Medtronic presents challenges. Elutia needs to be more innovative and gain more market share. The company must navigate intense competition and regulatory hurdles to achieve sustainable growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and is not financial advice. Market share data is approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elutia Inc.
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 2023-09-07 | Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://elutia.com |
Full time employees 51 | Website https://elutia.com | ||
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.